Management of Right Portal Vein Thrombosis

Initial Assessment and Diagnosis

Evaluate the extent of thrombosis using Doppler ultrasound as first-line investigation, followed by CT scan for confirmation and assessment of extension, to determine the appropriate treatment plan for patients with right portal vein thrombosis 1
Determine if the patient has underlying cirrhosis or other liver disease, as this may impact treatment options and outcomes 1
Assess for signs of intestinal infarction, such as severe abdominal pain, rectal bleeding, ascites, or multiorgan dysfunction, which requires urgent intervention 1
Rule out neoplastic portal vein thrombosis if there is underlying hepatocellular carcinoma using contrast-enhanced imaging, to guide treatment decisions 3
Consider screening for underlying genetic thrombophilic conditions, to identify potential risk factors for thrombosis 3

Start low-molecular-weight heparin (LMWH) at therapeutic dose immediately in the absence of major contraindications, as recommended by the American Association for the Study of Liver Diseases, for patients with right portal vein thrombosis 1, 2
For patients with cirrhosis, implement adequate prophylaxis for gastrointestinal bleeding before starting anticoagulation, to minimize the risk of bleeding complications 3
Monitor anti-Xa activity in overweight patients, pregnant patients, and those with poor kidney function, to ensure optimal anticoagulation 1
For patients without cirrhosis or with Child-Pugh A/B cirrhosis, LMWH, vitamin K antagonists (VKA), or direct oral anticoagulants (DOACs) are all reasonable options, according to the American College of Gastroenterology 2, 4
For patients with Child-Pugh C cirrhosis, LMWH alone is preferred, or as bridge to VKA in patients with normal baseline INR, as recommended by the European Association for the Study of the Liver 2

Continue anticoagulation for a minimum of 6 months, as recommended by the American Association for the Study of Liver Diseases, to reduce the risk of recurrent thrombosis 2, 3, 4
For patients awaiting liver transplantation, continue anticoagulation until transplant, to prevent thrombosis and improve outcomes 2, 3
For patients with superior mesenteric vein thrombosis or history of intestinal ischemia, consider lifelong anticoagulation, to reduce the risk of recurrent thrombosis 3
After portal vein recanalization, consider prolonging anticoagulation to prevent rethrombosis, as recurrence rates up to 38% have been reported when anticoagulation is stopped, according to the European Association for the Study of the Liver 3, 5

Perform cross-sectional imaging every 3 months to assess response to treatment, as recommended by the American College of Gastroenterology, to monitor thrombosis resolution and guide treatment decisions 4
Recanalization of the portal vein can be expected to occur up to 6 months after starting treatment, according to the American Association for the Study of Liver Diseases 1
If clot regresses, continue anticoagulation until resolution or transplantation, to prevent recurrent thrombosis 4
Time interval between diagnosis and start of anticoagulation less than 6 months is the most important factor predicting successful recanalization, as reported by the European Association for the Study of the Liver 5

Screen for esophageal varices before initiating anticoagulation, as recommended by the American Association for the Study of Liver Diseases, to identify patients at risk of variceal bleeding 2
Use either beta-blockers or band ligation to prevent variceal bleeding in patients with varices, according to the American College of Gastroenterology 5
Be aware that over half of patients not achieving recanalization will develop gastroesophageal varices during follow-up, as reported by the European Association for the Study of the Liver 1

Consider transjugular intrahepatic portosystemic shunt (TIPS) for liver transplant candidates with progressive PVT not responding to anticoagulation, or for patients with additional indications such as refractory ascites or variceal bleeding, as recommended by the American Association for the Study of Liver Diseases 3, 4
Avoid local thrombolysis due to high risk of major bleeding complications, as reported by the European Association for the Study of the Liver 1
Surgical thrombectomy has limited success and high recurrence rates, according to the American College of Gastroenterology 1

Overall bleeding complications with anticoagulation occur in approximately 5-14% of patients, as reported by the European Association for the Study of the Liver 5
Risk factors for bleeding include history of variceal bleeding, low serum albumin, and platelet count less than 50×10^9/L, according to the American Association for the Study of Liver Diseases 5
Severe portal biliopathy can develop in 30% of patients with acute PVT within 1 year, as reported by the European Association for the Study of the Liver 1